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CObjectives: Previous analyses of patient-reported outcome (PRO) label
claims concentrated only on successful label claims. The goal of this
research was to explore the reasons why PRO label claims were denied
and to compile regulatory feedback regarding the use of PROs in clinical
trials. Methods: By using the Food and Drug Administration’s Drug
pproval Report Web page, all new molecular entities and biologic
icense applications approved between January 2006 and December
010 were identified. For identified drug products, medical review
ections from publicly available drug approval packages were re-
iewed to identify PRO end-point status and any Study Endpoints
nd Label Development team comments. Results: Of the 116 new
olecular entities and biologic license applications with accompa-
ying drug approval packages identified and reviewed, 44.8% of the
roducts included PROs as part of the pivotal studies; however, only
4.1% received PRO label claims. Primary reasons for denial included O
, 200
al So
ttp://dx.doi.org/10.1016/j.jval.2012.01.010ssues of fit for purpose, issues of study design, data quality or in-
erpretation, statistical issues, administrative issues, and lack of
emonstrated treatment benefit. Conclusions: Based on drug ap-
roval packages, nearly half (45%) of new molecular entitity/biologic
icense application products in the years 2006 to 2010 included PROs
n the clinical trials supporting their approval, yet this rate is not
eflected by claims granted. Understanding the nature of PRO claims
ranted under the current regulatory guidance is important. In ad-
ition, a clear understanding of denied claims yields valuable in-
ight into where sponsors may improve implementation of PROs in
linical trials and submission of PRO evidence to increase the likeli-
ood of obtaining PRO label claims.
eywords: label claims, patient-reported outcomes, rejection.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Patient-reported outcomes (PROs) allow the voice of the patient to
emerge within the context of a clinical trial or observational study
and provide valuable insight into the patient experience beyond
that which can be measured by clinical indices alone. In some
diseases or conditions of interest, a PRO may be the sole source of
data from which drug efficacy can be measured, whereas in others
it may provide supplementary information on how the disease
and its treatment impact patients’ functioning and well-being.
PRO use is particularly common for products developed to treat
chronic, disabling conditions where the intention is not necessar-
ily to cure but to ameliorate symptoms, facilitate functioning, or
improve quality of life. PROs are the primary end points in clinical
trials evaluating drug products for disease areas such as irritable
bowel syndrome, migraine, and pain. PROs provide key supportive
data in many other disease areas, such as insomnia, asthma, and
psychiatric disorders. In oncology, PROs are commonly used to
assess both treatment benefits and toxicity to fully evaluate the
impact of treatment on health-related quality of life (HRQOL).
* Address correspondence to: Carla DeMuro, RTI Health Solutions
E-mail: demuromercon@rti.org.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.PROs can also be used in clinical trials to assess treatment satis-
faction, compliance, and caregiver burden [1].
Sponsors (i.e., pharmaceutical or biotechnology companies de-
veloping a new product) may choose to include a PRO end point to
support a label claim, to provide data supporting the primary end-
point, or as a source of data for communication and market-access
strategies. Regardless of the reason for a PRO’s inclusion in a clin-
ical trial, it is unique in that it captures the viewpoint of the patient
without input from others.
Willke and colleagues [2] conducted a review of drug labels to
understand the use of PROs compared with other trial end points.
That research identified the inclusion of PROs as efficacy
end points in approximately 30% of all labels reviewed between
1997 and 2002. In 2006, the Food and Drug Administration (FDA)
released a draft guidance for use of PROs in clinical trials, followed
by a final guidance in 2009, Guidance for Industry: Patient Reported
Outcome Measures: Use in Medical Product Development to Support La-
beling Claims [3], providing a blueprint for the use of PROs in clinical
trials. The guidance documents were intended to influence the
appropriate development, validation, and use of PRO measures to
facilitate a positive regulatory review in support of label claims.
Park Offices Drive, Research Triangle Park, NC 27709, USA.
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authored the PRO guidance in collaboration with other colleagues
from the FDA Center for Drug Evaluation and Research, the Center
for Biologics Evaluation and Research, and the Center for Devices
and Radiological Health. SEALD acts as an advisory board to the 17
Office of New Drugs reviewing divisions within the FDA and pro-
vides guidance pertaining to the development and validation of
study end points, clinical study protocol design, analysis, and in-
terpretation of study end points to support drug development,
labeling, and promotion.
According to the guidance, a claim is defined as a statement
of treatment benefit. Furthermore, a claim can appear in any
section of a medical product’s FDA-approved labeling or in ad-
vertising and promotional labeling of prescription drugs and
devices.
Since its release to the public, much interest has been paid to
the impact of this guidance document on the use of PROs and the
acceptance of PRO-based label claims [1,4,5,6]. Gnanasakathy and
colleagues [1] built on the work previously conducted by Willke
and colleagues [2] and reported the frequency of PROs in recently
approved drug labels. Specifically, these authors found that PRO
claims were granted for approximately 24% of all labels reviewed
between January 2006 and December 2010.
To date, however, no formal review has been undertaken to
examine PRO measures included in drug approval packages (DAPs)
but not appearing in approved labeling. Hence, there is no compi-
lation of feedback on the use of these PROs either by industry or by
regulatory authorities. Examination of these submissions may
provide an insight into the appropriate utilization of PROs by spon-
sors in clinical studies and additional guidance for preparing evi-
dence dossiers. This information may also provide regulators with
an overview to assess consistency in response across reviewing
divisions. Therefore, the purpose of this research was to review
the criticisms targeted at PRO end points for all new molecular
entities (NMEs) and biological license applications (BLAs) from
2006 through 2010 that utilized PROs in their clinical trials sup-
porting their approval but did not receive labeling claims for these
measures.
Methods
Data collection methods for this research are fully described else-
where [1]. Briefly, the FDA Drug Approval Reports Web page was
used to review new drugs that were approved in the United States
from January 2006 through December 2010, including only those
products classified by the Center for Drug Evaluation and Research
as NMEs or BLAs. Any product containing substances previously
marketed with a different brand name or set of indications, as a
different dosage form or strength, or as a combination product of
previously marketed entities was excluded.
Once products were identified, DAPs and approved product la-
bels were reviewed, and information was retrieved from the med-
ical review, summary review, cross-discipline team leader review,
and other review sections from the DAP as well as from the Indi-
cation and Clinical Studies section of the approved product label.
The DAPs were located on the FDA Web site Drugs@FDA (www.
accessdata.fda.gov). The following information was collected, as
publicly available, for each US drug product identified:
y Brand name
y Generic name
y Date of approval
y Applicant
y Label indication
y Utilization of PROs
y PROs mentioned in the DAP but not appearing in the label
y Evidence of claims sought but not grantedy Significance of the PRO results
y Division reviewer or SEALD reviewer feedback
Statistical analysis consisted of frequencies and cross-tabulations
of measured characteristics. Calculations were performed by us-
ing Microsoft Excel 2007. For analysis purposes, if a PRO appeared
in the DAP, it was considered to be an attempt to seek a PRO label
claim, despite sponsor intent, unless specifically noted otherwise.
Results
A total of 156 new drugs were approved between January 2006 and
December 2010. Of these, 33 were generic products and were ex-
cluded from our analysis, as were 4 new products that were ap-
proved but had no data available on the FDA Web site at the time
of review and three others were registered under multiple names
so were considered single entities. Therefore, this review includes
116 products.
Of the 116 products reviewed, 52 (44.8%) included PROs as part
of the pivotal studies; however, only 28 of the 116 (24.1%) received
at least one PRO claim [1]. A total of 26 products were identified as
having been denied a PRO label claim. For the purposes of analysis,
this included any product that had a PRO included in the DAP,
regardless of the sponsor’s intention, because it was not always
possible to determine whether a claim had been sought or
whether PRO data had been collected for other reasons. A subset of
products (n 6) received some or partial PRO labeling while other
requested PRO claims were denied within the same submission.
These six products were Azilect, Chantix, Letairis, Ampyra,
Bepreve, and Egrifta. Table 1 provides a listing of all 26 products
described in this review, arranged by the FDA division that granted
drug approval.
The filings for these 26 products included a wide range of PRO
measures, for example, symptom diaries, event logs, measures of
functioning and disability, symptom assessments (e.g., fatigue
and pain), disease-specific measures of HRQOL, generic assess-
ments of HRQOL, and utility measures. Table 2 provides an alpha-
betical listing of measures specified in the DAPs but not appearing
in the approved labeling.
To determine the rationale behind decisions to reject PRO
claims from the label, data specific to PROs mentioned in the DAP
Table 1 – Products with at least one claim denied by
FDA reviewing division.
FDA reviewing division Products reviewed
Anesthesia, analgesia, and
rheumatology products
Chantix, Ilaris
Antiinfective and
ophthalmology products
Lucentis, Bepreve
Biologic oncology: Vectibix
Cardiovascular and renal
products
Letairis, Samsca
Dermatology and dental
products
Stelara
Drug oncology Dacogen, Zolinza, Torisel, Ixempra
kit, Treanda, Istodax, Jevtana
Gastroenterology products Vpriv, Elaprase, Relistor
Medical imaging and
hematology products
Promacta
Metabolism and
endocrinology
Januvia, Egrifta, Somatuline
Neurology products Azilect, Ampyra
Psychiatry Invega, PristiqFDA, Food and Drug Administration.
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amination. The following coding convention was created and ap-
plied by a single rater to categorize the FDA reviewer’s (division or
SEALD) noted concerns regarding the PRO measure:
1. Fit for Purpose: lack of evidence of content validity (e.g., lack of link
between concept and claim, insufficient documentation of valida-
tion in population of interest, and full constellation of symptoms
not measured), recall period, or lack of evidence of proper trans-
lation or cross-cultural validation;
. Study Design, Data Quality, or Interpretation of Results: issues
of potential bias (open-label design, etc.), clinical meaningful-
ness, missing data, attrition rates, or improper completion;
. Statistical Analysis: no adjustment for multiplicity or inappro-
priate or missing statistical analysis plan;
. Administration Considerations: lack of documentation for
training or instruction in use of measure or copy of measure not
provided to the FDA; and
. No Treatment Benefit: not supportive of treatment benefit, im-
provement in certain symptoms but worsening in others, lack
of statistical significance, or FDA disagreed with sponsor.
xamination of the DAP for each product provided differing levels
f detail regarding why a measure was not included in the ap-
Table 2 – Alphabetical listing of measures with claims den
Measure
Body Image Impact Module
Borg’s Dyspnea Index
Caregiver Outcomes Assessment
Child Health Questionnaire–Child Form
Child Health Questionnaire, Parent Completed 50-Item Scale
Childhood Health Assessment Questionnaire
Chronic Idiopathic Thrombocytopenic Purpura Symptoms
Constipation Distress
Dermatology Life Quality Index
European Organisation for Research and Treatment of Cancer Quali
European Organisation for Research and Treatment of Cancer Quali
EQ-5D
Functional Assessment of Chronic Illness Therapy Fatigue Scale
Functional Assessment of Cancer Therapy–Breast Symptom Index
Health Assessment Questionnaire–Disability Index
Hospital Anxiety and Depression Scale
Hunter Syndrome–Functional Outcomes for Clinical Understanding
Hyponatremia Disease Specific Survey
Itch VAS
McGill-Melzack Present Pain Intensity scale
Modified Cigarette Evaluation Questionnaire
Multiple Sclerosis Walking Scale–12
Opioid Withdrawal Symptoms (modified Himmelsbach)
Pain Numerical Rating Scale (0–10 scale)
Parkinson’s Disease Quality of Life Scale
Patient Impression of Change in Bowel Status
Patient Reports of Bowel Consistency and Difficulty
Pruritis relief VAS
Quality of Life assessments by proxy
Short form-36
SF-36 Physical Functioning Scale
Sleep VAS
Subject Global Impression of Change
Symptoms and Quality of Life in Schizophrenia
Visual Function Questionnaire–25
Work Limitations Questionnaire
EQ-5D, EuroQol five-dimensional questionnaire; SF-36, Short Form 36roved labeling. Reasons for this included the proprietary natureof labeling discussions between sponsor and agency as well as
differences between products receiving a review by SEALD. De-
tailed feedback for each submission, by product, is provided in the
appendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2012.01.010.
“Fit for purpose” issues were the primary reasons for the denial
of PRO labeling claims, accounting for more than 38% of regulatory
feedback. A PRO measure that has been recognized by the FDA as
appropriate to support claims in a specific context (i.e., the mea-
sure meets the qualifications for supporting claims outlined in the
PRO guidance, specific to a study population and protocol and to
the claim sought/hypothesis tested) is described as “fit for pur-
pose” by the FDA.
As cited in the DAPs for 14 individual products, the FDA specif-
ically questioned the content validity and/or validity of instru-
ments in general, rationale in support of recall periods, and evi-
dence of appropriateness of translations for use in multinational
studies. This feedback was consistent, especially in regard to va-
lidity. Of the 14 products that fell within this category, 8 were
noted to have potential issues with the validity of the PRO measure
for the intended purpose. A SEALD review of the use of the SF-12
Health Survey (SF-12) and the Hyponatremia Disease Specific Sur-
vey as secondary end points in pivotal studies of Samsca provides
an illustrative example. In these studies, the sponsor included the
Life Questionnaire–Chronic Lymphocytic Leukemia 25
Life Questionnaire–C30
lth Survey; VAS, visual analogue scale.ied.
ty of
ty of
ScaleSF-12 and justified the use of the tool by pointing out that hypo-
l446 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 4 3 – 4 4 8natremia presents in a broad range of disease areas and that both
the physical and mental component scores of the SF-12 were used.
Reviewer feedback, however, noted: “The SF-12 was developed as
a generic health status instrument for the general population and
not as a symptom assessment tool or HRQoL tool in patients with
hyponatremia. As such the instrument is not effective as an as-
sessment of treatment benefit.” Regarding the Hyponatremia Dis-
ease Specific Survey, the SEALD reviewer explained that “the in-
formation submitted by the sponsor concerning the psychometric
properties of the HDS do not address the content validity and
therefore do not support the use of the instrument.” Similar feed-
back was provided in the Torisel review where FDA reviewers
noted that the “applicant did not provide evidence of validation of
the EQ-5D [EuroQol five-dimensional questionnaire] in the RCC
[renal cell carcinoma] population. It was used in a setting for
which it was not designed, and more frequently than intended.”
Issues of study design, data quality, or interpretation of results
was the second largest identified category and accounted for ap-
proximately 27% of the feedback for denied claims. In this cate-
gory, reviewers questioned the clinical meaningfulness of patient
responses, noted issues of bias introduced by open-label study
designs, and commented on missing data/dropout rates and other
indicators of data quality. These concerns were identified for nine
individual products. Regulatory feedback on Zolinza and Torisel
was illustrative of these points. The reviewer for the Zolinza sub-
mission stated, “PROs cannot be reliably measured in open label
studies . . . a 3-point improvement was considered clinically sig-
nificant, but the review does not state whether the proportion of
patients obtaining this level of relief was clinically meaningful.”
Missing data and potential for bias were noted in the Torisel re-
view. Neither Zolinza nor Torisel was granted PRO-related claims.
Statistical considerations that generated regulatory criticisms
included lack of or inappropriate statistical analysis plans such as
no planned adjustments for multiplicity. This issue is clearly de-
scribed in the regulatory review of Azilect. The reviewer noted, “I
cannot draw serious conclusions about the efficacy of these [PRO]
end points because of issues of multiplicity whereby the sponsor
did not make statistically appropriate adjustments for these mul-
tiple comparisons . . .” despite significant findings on the Parkin-
son’s Disease Quality of Life scale in favor of Azilect. Although it is
unknown how this adjustment may have impacted the result and
subsequently the label claim, the expectations of the reviewing
division are well documented.
In addition, administrative considerations impacted agency re-
viewer decision making. Concerns were noted regarding the lack
of appropriate documentation describing training procedures, ad-
ministration of the tool, and inadequate descriptions of measures.
Examples of such concerns included the SEALD reviews of Egrifta
where reviewers noted a missing user’s manual, lack of descrip-
tion of the Caregiver’s Outcome Assessment for Torisel, and con-
fusion regarding patient instructions for using an itch visual ana-
logue scale for Stelara.
A final category grouped agency reviewer feedback on PRO
measures where discrepancies occurred between the agency and
the sponsor regarding whether a measure appropriately demon-
strated treatment benefit. Feedback in this category ranged from a
straight-forward assessment of no demonstrated statistical differ-
ence between active treatment and placebo (e.g., Letairis and Reli-
stor) to more detailed discussions of failure to demonstrate treat-
ment benefit when some symptoms improved while others
showed worsening (e.g., Chantix).
Figure 1 depicts the percentage of claims denied by each ana-
ytic category of reasons for rejections, and Table 3 describes reg-
ulatory feedback by product.
Case studies of each drug submission are detailed in the Sup-
plemental Materials found at http://dx.doi.org/10.1016/j.jval.2012.
01.010. Differing levels of information were provided in each DAP;likewise, review formats were somewhat inconsistent. Therefore,
the level of detail extracted from the submissions varies by prod-
uct. For the purposes of this review, it was assumed that the spon-
sor sought a claim based on the PRO(s) referenced in the DAP un-
less otherwise specified.
Discussion
To our knowledge, this is the first comprehensive compilation of
FDA feedback on the use of PROs in clinical trials in support of label
claims since the release of the draft FDA guidance in 2006. Reasons
for rejection of claims varied, but the majority focused on whether
a measure was fit for the purpose for which it was used and issues
of study design, data quality, or interpretation of PRO results. Most
denials and critical discussions were consistent with the spirit of
the PRO guidance. The final PRO guidance places strong emphasis
on interpreting PRO data and on developing PRO measures. Instru-
ment validity, in particular content validity, is discussed in detail
in the PRO guidance. The guidance notes that other measurement
properties will not be considered until evidence of this property
has been appropriately determined. Reviewers emphasized this in
their criticisms in a number of product reviews, including several
that utilized generic measures.
Concerns with study design and interpretation of PRO data per-
sist. For example, reference to minimal important difference was
removed from the final guidance and replaced with a discussion of
individual responses to treatment or responder definitions. This
change, however, does not completely address the issue of dem-
onstrating a clinically relevant change. Clinical trial consider-
ations are addressed in the guidance, but these issues do not al-
ways have a solution that is practical for all clinical trial conditions
(e.g., single-arm study design in oncology studies).
Statistical considerations also remain paramount to obtaining
PRO claims. Responses to submissions clearly demonstrate that
PROs must be treated with the same rigor as other clinical end
points. Prospective, adequate statistical analysis plans must be
developed to address issues such as multiplicity and methods for
dealing with missing data.
Importantly, as this review period is inclusive of the release of
both the draft and final guidance documents, the level and type of
documented feedback provided to the public by the FDA is incon-
sistent. First, the level of review varied across submissions. Not all
submissions received a review from SEALD, because this group
acts on a consultancy basis. Submissions with a SEALD review
Fit for Purpose
38%
Study Design, Data 
Quality, Interpretation
27%
Statistical Issues
11%
Administrative Issues
10%
No Treatment Benefit
14%
Fig. 1 – PRO label claim denials.(e.g., Stelara, Chantix, Samsca, and Egrifta) received very detailed
al cat
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were much more difficult to discern and were found embedded
within the medical review or cross-team leader review. Comments
from the SEALD review of Egrifta illustrated the difficulties facing
both industry and regulatory bodies in the review of studies uti-
lizing PROs that were planned and executed prior to the release of
the draft guidance. Specifically, the SEALD reviewer expressed res-
ervations with respect to the content validity of the Body Image
Impact Module, which does not meet the new standards articu-
lated in the guidance; the reviewer stated that the instrument
should not be recommended by FDA for future drug development,
yet a claim was still granted. It is worth noting that the PROs eval-
uated in the Egrifta clinical trials had been incorporated with prior
input from the FDA in advance of the final guidance. As experience
with the guidance matures and both industry and regulatory bod-
ies acclimate, such conflicts are expected to become less frequent.
Other inconsistencies in regulatory responses may be attribut-
able to differences between reviewing divisions. For example, in
some situations, a generic measure (e.g., the Short Form 36 Health
Survey’s physical component score) was accepted as a suitable
end point by one reviewing division and rejected by another be-
cause of a lack of specificity. In addition, differences in the per-
ceived acceptability of PRO measures to support labels claims may
exist across FDA divisions. At the time of this analysis, no PRO
claims have been granted by the oncology division, but PRO data
for some oncology drugs (e.g., Dacogen) appear to demonstrate
significant results regarding impact on HRQOL or symptoms such
as fatigue and dyspnea. Although it is likely that these data were in
some way confounded by the nature of the trial, sponsors would
better understand the position of this division if details were pro-
vided in the reviews. Disclosing the measures used by sponsors
and the reason for criticisms, if any, would greatly assist sponsors
in refining their internal decision-making processes to include the
Table 3 – Category of denial by product.
Product Fit purpose Study design, data
quality, interpretation
Stat
Azilect
Chantix X
Dacogen*
Luncentis X
Elaprase
Vectibix XX
Zolinza XX
Januvia
Torisel X XXXX
Letairis X
Somatuline X
Ixempra XX
Relistor XX
Samsca XX
Ilaris X
Stelara XXXXXX
Bepreve X
Isodax XX XX
Ampyra X X
Jevtana XXX XXXX
Egrifta XXXX
Invega
Pristiq X
Treanda*
Promacta*
Vpriv X
* No information provided in the drug approval package. X, analyticright instrument to measure the right concept.Several limitations should be noted for this review. First, for
practical reasons we limited review of products to those classified
as NMEs and/or BLAs. As such, products seeking approval for new
indications were not included in our review. There may be in-
stances where these submissions also have rejected PRO claims. A
limitation of this analysis is that it is not clear, because of the
confidential nature of labeling discussions, whether the com-
ments by the FDA were for claims actively requested by sponsors
or whether they were comments made in some other regard. PRO
instruments are included in drug submissions not only for label
claims but also to provide supportive data to the primary end
point, to provide data requested by the FDA or the European Med-
icines Agency [5], for publication purposes, or to satisfy market-
access needs (utility assessments). Unless actively seeking a label
claim, the sponsor is unlikely to invest in new instruments to meet
the standards outlined in the FDA PRO guidance. Therefore, al-
though this analysis provides sponsors a means with which to
assess and support the quality of their PRO strategies, our analysis
is unlikely to be a measure of the quality of submissions targeted
at PRO label claims to the FDA, because often the lack of access to
a detailed response from the agency made it difficult to discern the
rationale for these types of decisions.
Conclusions
The use of PROs as clinical trial end points continues to be wide-
spread, with more than 45% of all NME or BLA submissions be-
tween 2006 and 2010 utilizing these instruments in some capacity
[1]. Despite the commonality of PRO inclusion, rejection rates for
PRO claims remain high. PRO label claims are denied for various
reasons, some of which are addressed by the FDA in its PRO guid-
ance. Although the learnings from this research are limited by the
l issues Administrative issues No treatment benefit
X
X
X
X
X
X
X
X
X
X
X X
XXX
X
X X
egory for denied claim.istica
X
X
X
X
X
X
Xamount of information publicly available, review of denied claims
448 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 4 3 – 4 4 8may provide an insight into how sponsors could improve the im-
plementation of PROs in clinical trials and the level of PRO evi-
dence submitted to increase the likelihood of obtaining PRO label
claims. Such continuous learning and combined efforts between
sponsors and regulatory bodies will allow the patient’s voice to be
heard in the drug development process.
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